|
REGN-COV2
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. is a combination medicine used for the treatment and prevention of COVID-19, COVID19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent Drug resistance, mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals. The most common side effects include allergic reactions, which include infusion related reactions, injection site reactions, brief pain, weakness and others. The combination is approved under the brand name Ronapreve for medical use in Japan, the United Kingdom, the European Union, and Australia. In ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. Company history The company was founded by CEO Leonard Schleifer and scientist George Yancopoulos in 1988. Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation. On March 26, 2012, Bloomberg announced that Sanofi and Regeneron were in development of a new drug that would help reduce cholesterol up to 72% more than its competitors. The new drug would target the PCSK9 gene. In July 2015, the company announced a new global collaboration with Sanofi to dis ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |